DDR2 mutation serves as an inclusion eligibility criterion in a clinical trial targeting MGCD516, a receptor tyrosine kinase inhibitor, for patients with NSCLC, or metastatic tumors (https://www.mycancergenome.org). This evidence concerns the gene NTRK1 and metastatic neoplasm.